Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) closed an upsized underwritten public offering on March 12, 2026, raising approximately $719 million in aggregate gross proceeds before fees. The offering comprised 8,470,989 common shares (including 1,157,407 option shares) and pre-funded warrants to purchase 402,468 shares.
Pre-funded warrants were priced at $80.999 with a $0.001 exercise price and are exercisable immediately. Net proceeds will fund clinical and preclinical development, commercial readiness, working capital, and general corporate purposes.
Positive
- $719M aggregate gross proceeds raised from the offering
- Issued 8,470,989 common shares including full 1,157,407 underwriter option exercise
- Sold 402,468 pre-funded warrants exercisable immediately at $0.001
Negative
- Immediate share dilution from issuance of common shares and pre-funded warrants
- Underwriting discounts and offering expenses will reduce net proceeds available
- Large capital raise may pressure near-term share supply and trading dynamics
News Market Reaction – DNTH
On the day this news was published, DNTH declined 3.06%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $115M from the company's valuation, bringing the market cap to $3.66B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DNTH was modestly lower pre-news (-1.24%) while close peers showed mixed, mostly small moves (e.g., ELVN +2.9%, NTLA -2.47%). No broad biotech rotation matched this activity.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Offering pricing | Negative | -1.2% | Priced upsized $625M offering with common shares and pre-funded warrants. |
| Mar 09 | Offering proposed | Positive | +9.7% | Proposed $400M underwritten public offering with 30-day underwriter option. |
| Sep 11 | Offering closing | Negative | -1.9% | Closed upsized $288M offering including full underwriter option exercise. |
| Sep 09 | Offering pricing | Positive | +6.5% | Priced $251M upsized offering at $33 per share and pre-funded warrants. |
| Sep 08 | Offering proposed | Positive | +11.9% | Announced proposed $150M underwritten offering plus $22.5M over-allotment. |
DNTH’s offering-related headlines have consistently seen price moves in the same direction as the initial reaction, with positive responses to proposed/pricing announcements and modest declines on closing notices.
Over the past two years, Dianthus has repeatedly tapped equity markets via underwritten offerings. In September 2025, it moved from a proposed $150 million deal to an upsized $288 million closing. In March 2026, it scaled further, progressing from a proposed $400 million raise to pricing an upsized $625 million offering. Those events produced double‑digit moves both up and down, underscoring how capital‑raising news has been a key driver for DNTH’s trading.
Historical Comparison
Across the last 5 offering headlines, DNTH saw an average move of 5.01%, showing that capital-raising news has typically driven meaningful price reactions.
Offering history shows progression from a proposed $150M raise in 2025 to repeated upsized deals in 2026, reflecting increasing scale of equity financing activity.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2026-01-28 registers up to $600,000,000 of mixed securities. It has already been used via multiple 424B5 takedowns in March 2026, including the current upsized offering, giving the company flexibility to raise additional capital over time.
Market Pulse Summary
This announcement confirms closing of an upsized equity raise, with gross proceeds of about $719M at $81.00 per share plus pre-funded warrants. It follows a series of offerings drawn from a $600M shelf and continues a strategy of funding late‑stage autoimmune programs through equity. Investors may focus on how efficiently new capital advances trials and commercial readiness, and on future financing cadence relative to development milestones.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
form s-3 regulatory
rule 462(b) regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,157,407 shares, at a public offering price of
Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and general corporate purposes.
Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair acted as joint book-running managers for the offering. LifeSci Capital acted as Dianthus’ financial advisor.
The offering was made pursuant to a shelf registration statement on Form S-3 relating to the securities that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on January 30, 2026 and a related registration statement that was filed with the SEC on March 10, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). The offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov., and may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding Dianthus’ expectations regarding the use of proceeds from the public offering and the potential value and clinical benefit of the Company’s product candidates. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart, DNTH212 or the Company’s other compounds may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
